Method for producing lipstatin through microbial fermentation and culture medium

Abstract

The invention provides a method for producing lipstatin through microbial fermentation, and a used fermentation culture medium. The method comprises the following steps: inoculating streptomyces toxytricini into the fermentation culture medium, adding Mg<2+>, Co<2+> and Zn<2+> with the final concentrations of 10-15 mmol / L, 0.5-2.0 mmol / L and 0.1-0.5 mmol / L respectively in the culture medium, conducting fermental cultivation at 220 r / min and at the temperature of 28 DEG C, adding aminocaproic acid on the fourth day of fermental cultivation to enable the final concentration of the aminocaproic acid to be 40-50 mmol / L, adding n-caprylic acid on the sixth day of fermental cultivation to enable the final concentration of the n-caprylic acid to be 30-40 mmol / L, and keeping the total fermental cultivation time to be 150-180 hours, so as to obtain the lipstatin from the fermentation liquid after the fermentation is completed. According to the invention, the addition combination of a precursor and metal ions affecting the fermentation and synthesis of the lipstatin is optimized, and the best combination of the precursor and the metal ions is found, so that the yield of the lipstatin is remarkably increased, the potency is remarkably improved after the method and the culture medium are applied to the industrial production of the lipstatin, and the cost is lowered.

Description

(1) Technical field [0001] The invention relates to a method for producing riprestatin by microbial fermentation and a used fermentation medium. (2) Background technology [0002] Lipstatin is a metabolite produced by fermentation of Streptomyces toxytricini, and its tetrahydro derivative is orlistat, a weight-loss drug successfully developed by Roche ( Xenical), Orlistat is the first gastrointestinal lipase inhibitor, which inactivates the enzyme by forming a covalent bond with the active serine site of gastric lipase and pancreatic lipase in the lumen of the stomach and small intestine, reducing Decomposition and absorption of fat, so as to achieve the role of weight control. Orlistat is currently the only weight-loss drug that does not enter the blood and does not act on the central nervous system. [0003] Orlistat can be synthesized by total chemical synthesis or by first producing liprestatin by fermentation synthesis followed by hydrogenation. Due to the relatively...

AI Technical Summary

Problems solved by technology

European patent EP0803567 describes the process of improving liprestatin by adding linoleic acid, octanoic acid and N-formyl-L-leucine or leucine during the fermentation process, but the fermentation level is relatively low, less than 1g / L

Images